logo-loader

Q BioMed CEO says Strontium89 has received a warm response and enthusiasm from physicians

Published: 09:37 21 Sep 2020 EDT

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the biotech has seen commercial uptake of Strontium89, its FDA-approved drug for the non-opioid treatment of metastatic cancer in the bone. Corin says while the coronavirus pandemic slowed the diagnosis and treatment of cancer in many patients throughout spring and into summer, limited the industry's access to physicians, the reintroduction of Strontium89 has received a warm response and enthusiasm from physicians, who are pleased that it is once again available for the benefit of their patients.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 31 minutes ago